BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21709316)

  • 1. A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables.
    Endesfelder D; McGranahan N; Birkbak NJ; Szallasi Z; Kschischo M; Graham TA; Swanton C
    Oncotarget; 2011 Jul; 2(7):529-37. PubMed ID: 21709316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.
    Roylance R; Endesfelder D; Gorman P; Burrell RA; Sander J; Tomlinson I; Hanby AM; Speirs V; Richardson AL; Birkbak NJ; Eklund AC; Downward J; Kschischo M; Szallasi Z; Swanton C
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2183-94. PubMed ID: 21784954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
    Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
    Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical relationship between chromosomal instability and survival outcome in cancer.
    Birkbak NJ; Eklund AC; Li Q; McClelland SE; Endesfelder D; Tan P; Tan IB; Richardson AL; Szallasi Z; Swanton C
    Cancer Res; 2011 May; 71(10):3447-52. PubMed ID: 21270108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
    Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
    Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting features of breast cancer with gene expression patterns.
    Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
    Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features.
    Akbar M; Akbar K; Naveed D
    J Ayub Med Coll Abbottabad; 2014; 26(3):290-3. PubMed ID: 25671929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
    Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.
    Endesfelder D; Burrell R; Kanu N; McGranahan N; Howell M; Parker PJ; Downward J; Swanton C; Kschischo M
    Cancer Res; 2014 Sep; 74(17):4853-4863. PubMed ID: 24970479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
    Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
    Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer.
    Szász AM; Li Q; Eklund AC; Sztupinszki Z; Rowan A; Tőkés AM; Székely B; Kiss A; Szendrői M; Győrffy B; Szállási Z; Swanton C; Kulka J
    PLoS One; 2013; 8(2):e56707. PubMed ID: 23468873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern pathologic diagnostics in breast cancer].
    Szoke J; Udvarhelyi N
    Orv Hetil; 2012 Jan; 153(1):22-30. PubMed ID: 22204831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
    Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C
    J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.